Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    A new Revision tag shows v3.6.6, replacing v3.6.5, indicating a platform update. It represents an internal software version change rather than a modification to the study content or user-facing information.
    Difference
    0.1%
    Check dated 2026-08-29T23:41:52.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The revision tag in the page footer was updated from v3.6.4 to v3.6.5, indicating a newer version of the page. This change updates the page metadata without affecting the study details, layout, or user interactions.
    Difference
    0.1%
    Check dated 2026-08-08T23:25:26.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page now shows a new revision tag indicating a software update (from v3.6.3 to v3.6.4); this reflects a backend change and does not alter the study details or user-visible information.
    Difference
    0.1%
    Check dated 2026-07-25T17:45:58.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The site version was updated from v3.6.2 to v3.6.3, indicating a software update or patch. This likely includes minor fixes or improvements without altering the study content displayed on the page.
    Difference
    0.1%
    Check dated 2026-07-04T09:20:29.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The page's revision tag changed from v3.6.0 to v3.6.2, indicating an update to the Study Record page version. This update reflects maintenance or enhancements to the page layout or metadata rather than changes to trial data.
    Difference
    0.1%
    Check dated 2026-06-27T07:39:49.000Z thumbnail image
  9. Check
    88 days ago
    Change Detected
    Summary
    The study page now communicates that recruitment has ended and adds new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) while adjusting the Interventions header and noting a new revision tag (Revision: v3.6.0).
    Difference
    0.4%
    Check dated 2026-06-13T00:31:45.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.